<DOC>
	<DOCNO>NCT00305747</DOCNO>
	<brief_summary>RATIONALE : Diindolylmethane may slow growth prostate cancer cell . PURPOSE : This phase I trial study side effect best dose diindolylmethane treat patient nonmetastatic prostate cancer respond previous hormone therapy .</brief_summary>
	<brief_title>Diindolylmethane Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Establish maximum tolerate dose , dose-limiting toxicity , recommend phase II dose absorption-enhanced diindolylmethane ( BioResponse-DIM^® [ BR-DIM ] ) patient nonmetastatic , hormone-refractory prostate cancer rise serum prostate-specific antigen ( PSA ) level . - Evaluate toxicity BR-DIM . Secondary - Evaluate plasma pharmacokinetics twice daily oral administration BR-DIM patient population . - Evaluate effect BR-DIM supplementation serum PSA level . - Correlate change expression level lymphocytes NF-kB serum PSA level patient take BR-DIM supplementation . - Determine quality life measure patient take BR-DIM supplementation . OUTLINE : This open-label , dose-escalation study . Patients receive oral absorption-enhanced absorption-enhanced diindolylmethane ( BioResponse-DIM^® [ BR-DIM ] ) twice daily day 1-28 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos BR-DIM maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . Quality life assess baseline , day 1 course , completion study therapy . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma prostate Prostate specific antigen ( PSA ) failure local therapy ( surgery , radiation therapy , brachytherapy , cryotherapy ) Rising PSA despite androgendeprivation therapy castrate level testosterone ( &lt; 50 ng/dL ) Two successive rise PSA level least 1 week apart PSA ≥ 5 ng/mL Patients history combine hormonal therapy must continue luteinizinghormone releasinghormone agonist treatment must demonstrate rise PSA antiandrogen withdrawal No evidence distant metastasis bone scan CT scan No known brain metastasis require active therapy PATIENT CHARACTERISTICS : ECOG performance status ≤ 3 Life expectancy ≥ 12 week Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGOT and/or SGPT ≤ 2.5 time ULN AND alkaline phosphatase normal OR alkaline phosphatase ≤ 4 time ULN AND SGOT and/or SGPT normal Creatinine clearance ≥ 60 mL/min OR creatinine normal Fertile patient must use effective contraception None follow condition within past 6 month : Myocardial infarction Severe unstable angina Symptomatic congestive heart failure Cerebrovascular accident transient ischemic attack Coronary/peripheral artery bypass graft No severe acute chronic medical psychiatric condition laboratory abnormality would preclude study participation PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 28 day since prior radiotherapy At least 28 day since prior investigational agent treatment prostate cancer At least 4 week since prior flutamide At least 6 week since prior bicalutamide No concurrent antineoplastic agent No concurrent warfarinrelated anticoagulant No concurrent protonpump inhibitor drug gastroesophageal reflux disease ( e.g. , rabeprazole , esomeprazole magnesium , lansoprazole , omeprazole , pantoprazole sodium ) No concurrent micronutrient supplement dietary soy product One daily multivitamin allow</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>